Aclarion Reports Growing Adoption of Nociscan at The London Clinic, Supported by New Physician Video

Aclarion announces nearly 100 Nociscan procedures at The London Clinic, highlighting increased clinical adoption and physician confidence in using the biomarker-based AI tool for chronic low back pain evaluation.

Houston Metrowire Staff
Healthcare
Aclarion Reports Growing Adoption of Nociscan at The London Clinic, Supported by New Physician Video

Aclarion, Inc. (Nasdaq: ACON, ACONW) today released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, discussing his real-world experience with Nociscan. The video, available here, underscores the growing integration of the non-invasive diagnostic tool in routine clinical practice. To date, nearly 100 Nociscans have been performed at The London Clinic, one of the United Kingdom’s leading private hospitals, reflecting sustained physician engagement and increasing utilization for chronic low back pain evaluation.

Mr. Sutcliffe, who also serves as Lead Clinician at The London Spine Clinic, brings over 30 years of experience treating spinal conditions. In the video, he emphasizes how Nociscan provides an additional layer of insight that complements traditional imaging. “Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain,” said Mr. Sutcliffe. The technology leverages MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain, helping physicians differentiate between painful and non-painful discs in the lumbar spine.

Brent Ness, Chief Executive Officer of Aclarion, noted the significance of approaching 100 scans at a leading international center. “This video offers a compelling perspective on how Nociscan is being used in day-to-day clinical practice,” said Ness. “Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain.” Chronic low back pain affects approximately 266 million people worldwide, and clinical data have demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.

For more information about Nociscan and to find a nearby center, visit the company’s site map here. Additional news from Aclarion is available on their latest news page.

Blockchain Registration

QR Code for Blockchain Registration